Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female Chinese subjects~* Age between 18 to 55 years (both inclusive) at the time of signing informed consent~* Body mass index (BMI) between 20 and 24.9 kg/sqm (both inclusive)~* Body weight greater than or equal to 54.0 kg~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential not using an adequate contraceptive method throughout the trial including follow-up period. Adequate contraceptive measures are sterilisation, intrauterine device (IUD), oral contraceptives or barrier methods~* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases~* Use of prescription or non-prescription systemic products (including routine or non-routine vitamins or herbal products) or topical medicinal products (except paracetamol and oral contraceptives) within 3 weeks (or within 5 half-lives of the medicinal product, whichever is longest) prior to Visit 2 (randomisation)~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2~* History of pancreatitis (acute or chronic)~* Calcitonin greater than or equal to 50 ng/L~* Blood donation, surgery or trauma with significant blood loss (400 mL) within the last 12 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
- Semaglutide 0.5 mg placebo (Type: PLACEBO_COMPARATOR): Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
- Semaglutide 1.0 mg placebo (Type: PLACEBO_COMPARATOR): Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).